|
Chelation Therapy
What is Chelation Therapy?
Pronounced “Key-lay’-shun,” Chelation Therapy is one of the most
effective treatments for a wide spectrum of diseases or aging
conditions. But it is more than a treatment, it is a preventive process
and most certainly a treatment of the 21st century effectively
practiced by many physicians today. It is the only therapy
where physicians who practice it habitually use it on themselves and
their loved ones as either curative or preventive treatment. Critics
of Chelation Therapy have never used it on themselves, nor their
loved ones, nor on their patients, nor have they read the
voluminous literature that has been compiled by various
physicians and scientists who are members of the American College
of Advancement in Medicine1 (ACAM),
an organization dedicated to certification in the practice of Chelation
Therapy and to further its research.
In Chelation Therapy, the imagery is often used of the lobster claw,
grabbing onto a cation -- a positive metal ion -- in the blood stream
during the process of surrounding a positive (metal) ion. The chemical
equivalent of the lobster claw is a protein, an amino acid called EDTA
(Ethylene Diamine Tetracetic Acid). EDTA combines with cations in the
blood stream, flushing them out with urine. Do not think, however,
that this is the only form of chelation that can take place within
the body. The most common form of chelation is that which takes place
during strenuous exercise, producing lactic acid, a natural chelater.
According to James J. Julian, M.D.2 “Chelation
is a basic process of life itself. Without the chelation mechanism,
life as we know it would not exist on this planet.
“Chelation is the process that enables plants to take inorganic
elements and change them into organic plant structure.
Chlorophyll of green plants is a chelate of the mineral magnesium;
blood hemoglobin (the oxygen carrier) is a chelate of iron. Chelation
is the process by which the body utilizes aspirin, penicillin,
vitamins, minerals and trace elements."
Chelation is a natural process found in nature. Soap is a chelator,
taking off grime and dirt. When you soften water through a house
water-softener, you use a chelating agent to take out minerals. EDTA,
when used in your 100,000 miles of internal plumbing called
capillaries, veins and arteries, acts in a similar manner, by taking
out metal ions that will otherwise damage us7.
As Julian2 further
explains, "A modified copy of one of these natural amino acids
called ethylene diamine tetracetic acid (EDTA), is used in Chelation
Therapy. It is modified to make it more predictable and dependable in
removing specific elements with [positive] electric charges such as
calcium and heavy metals; namely lead, arsenic, mercury, cadmium and
aluminum from the body.”
In 1893, Swiss Nobel Laureate Alfred Werner proposed a theory of metal
which provided the foundation for modern chelation therapy10,
11. In the early 1930's Germany and the United States both
experimented with chemical processes for synthesizing EDTA11.
Chelation therapy was first used by the British in WWII as an antidote
to poison gas inhalation. According to John Parks Trowbridge, M.D. and
Morton Walker, "The earliest reported research using EDTA for removal of
plaque-producing calcium deposits was conducted in 1946 at the
University
of Zurich, and in 1947 and 1948 at the
University
of Bern39." In 1948
the U.S. Navy used EDTA to treat lead poisoning. Dr. Norman E. Clarke,
Director of Research at
Providence
Hospital in Detroit, observed that after a series of treatments with
EDTA, patients' overall health appeared to improve. Patients who had
angina reported that their chest pain was gone. Others with gangrene of
the legs reported healing. Memory, sight, hearing and sense of smell all
improved. People treated with chelation reported increased vigor11.
Clarke's observations stirred up interest in physicians who reported a
wide-range of benefits to patients suffering from heart disease, brain
disorders, and arteriosclerosis. It was clear that EDTA was effective
not only in removing toxic metals, but also in helping restore blood
vessels blocked by placque.
In 1952 W. Grant, M.D., in a research paper, "described the use of EDTA
chelation therapy as a solution for removing calcium from the eyes of
human patients with post-keratitis corneal opacities which had resulted
in cataracts39."
During the 1960's there was demonstrated a wide-range of benefits to
patients suffering from various diseases. These demonstrations included
both human and animal studies. In particular, "That EDTA is able to
remove calcium from the arterial wall was conclusively shown in a study
by Fred Walker, Ph.D. and outlined in his doctoral thesis39."
But, a serious blow to EDTA study occurred in 1969 when a patient
expired. This resulted in reduced motivation to establish the positive
effects of EDTA in cardio-vascular and age-associated diseases11.
During the 1970's there were numerous medical/legal battles surrounding
chelation therapy. Some MD's were placed on probation by their State
Medical Boards. (This battle continues in certain states to this day.)
Others have won battles which allowed them to use EDTA, which was
approved by the FDA for metal toxicity. Other State Medical Boards
either ignored the dispute, or tacitly approved the use of Chelation
Therapy. Chelation Therapy is a treatment not generally accepted
by the general medical establishment. In those few states where
medical boards have closed down or prosecuted physicians who practice
Chelation Therapy, the State Medical Boards for the most part
consist of well-meaning physicians who are concerned with our welfare
(and their own pocketbooks in some cases), but who know absolutely
nothing about the therapy other than what they’ve read that was
written by others who knew nothing about it. It is safe to say that
every article written against Chelation Therapy and
printed in “respectable” journals has been written by a physician
or researcher who has assumed the mantle of Authority, yet has
absolutely no knowledge of it. A presumed exception is a study performed
by Danish surgeons (with conflict of interest) and published in the 1991
American Journal of Surgery and in the Journal of Internal
Medicine 231:261-267 1992. It is clear from an analysis performed by
the American Institute of Medical Preventics44 that
this study was either done in total ignorance of the appropriate
methodology of scientific studies or, most probably, was fraudulently
designed to cast aspersions against this otherwise wholly successful
treatment for financial gain. Contrary to wide-spread opinion, neither
science or the field of medical practice is free of fraud, dishonesty
and incompetence.
In 1973 the American Academy of Medical Preventics (now the
American
College of Advancement in Medicine [ACAM]) developed a safe and
effective protocol for this therapy. Since that time more than half a
million people have been helped according to documented case histories,
"most of them victims of hardening of the arteries39."
According to James P. Frackelton, President of the American Institute of
Medical Preventics (AIMP), AIMP "is the holder of an Investigational
New Drug permit issued by the U.S. Food and Drug Administration and is
cosponsor of [an] ongoing FDA approved stud[y]of EDTA chelation therapy
to treat atherosclerotic peripheral vascular disease with claudication.
AIMP works closely with FDA officials to ensure that the studies are
meticulously conducted, and that all FDA requirements can be met. If and
when the studies are successful, the FDA would then approve
atherosclerosis to be listed on the package insert of MgEDTA45."
This therapy historically began with the use of Calcium EDTA as a
treatment for lead poisoning, called plumbism, after the chemical
name for lead, plumbum. If you remember history, you’ll recall that
the
Roman Empire
was gifted with great engineers, and those engineers created a
gigantic system of water plumbing made of lead. Some historians have
hypothesized that lead poisoning from water contacting tubes of lead,
and dissolving lead compounds, was a contributing factor to the
downfall of the
Roman Empire.
But you don’t have to go as far back as the Roman Empire to observe
lead poisoning. It was only rather recently that the U.S. Government
banned lead from automotive gasoline engines, and also from interior
paints which have poisoned so many children whohave unwittingly eaten
peeling lead paint.
Various doctors have been called upon from time to time to use Calcium
EDTA chelation to rid a patient of lead poisoning acquired by one
means or another, such as inhaling the fumes from the burning of
lead batteries. In this process, the physician inserts a needle into
the bloodstream and “pushes” a one-shot substance into the veins
in the recognition that a chelating chemical will grab onto
poisonous lead in the body, surround it, and allow the body to flush
the poison out with the patient’s urine.
That’s the extent of knowledge that most physicans have about
Chelation Therapy. If you ask them if they know anything about
Chelation Therapy, they’ll say “Yes!” thinking that you mean
this single-push process developed in 1948 for ridding the body of
excessive lead. Some fewer physicians will know of the use of flushing
out bone-attractive materials such as plutonium.
EDTA Chelation Therapy described herein is gentler than the one-shot
lead “push” and in many ways more beneficial. EDTA can surround,
combine with and flush out many unwanted substances, such as calcium,
lead, arsenic, aluminum and, indeed, any positive ion that is
undesired and capable of being combined with this amino acid. Calcium
EDTA is usually used for lead poisoning, whereas disodium EDTA is
usually used in the described Chelation Therapy. Magneisum EDTA is being
used with increasing frequency. At the termination of infusion of
disodium EDTA, Calcium Gluconate is often placed in the infusion bottle,
converting the remainder of the EDTA to Calcium EDTA, to help prevent
calcium tetony. However Calcium, disodium and Magnesium EDTA are all
suitable for their various purposes. Gordon E. Potter, M.D. reports that
while EDTA is excellent for bivalent ions, Desferroxamine is superior
for chelating out trivalent ions such as Iron (Fe+++)
and Aluminum (Al+++).
Since Desferroxamine passes through the blood brain barrier, it may also
be superior for Alzheimer's disease; i.e. in chelating out aluminum. He
has no knowledge of the safety of using EDTA and Desferroxamine at the
same time, however46.
According to Warren M. Levin, M.D." EDTA binds mercury avidly in
vitro (in the test tube), but is ineffective in vivo (in the
human body)47."
There are many poisons that we breathe in, eat, drink or are
exposed to by bodily contact and skin absorption. The subject of
environmental pollution is entirely too big to describe here, but
everyone who reads newspapers, watches television, or hears radio
will surely know that our bodies are currently bathed in
undesirable pollutants of every kind. EDTA Chelation Therapy cannot
rid us of everything foreign, of course, but it does an excellent job
of chelating out many undesirable pollutants.
How Does Chelation Therapy Work?
While EDTA Chelation Therapy will "flush out" many undesirable
substances, a chief effect is to contact, combine with and to flush out
calcium that is found in plaques in the arteries.
The molecules and atoms that “seek” out or have a very strong
affinity for, other compounds and atoms are called “free radicals.”
Free radicals are always formed within the body as a natural consequence
of a balance between catabolism and anabolism, the building up and
breaking down of cellular tissue, respectively. Free radicals also have
a vital place in killing foreign micro-organisms. Whenever the balance
is seriously upset, and especially for extended periods, when more free
radicals are formed than can be balanced off by natural bodily
processes, disease and often accompanying inflammation occurs.
Chelation Therapy has a definite place in the ridding of
free-radicals that cause inflammation. It performs other duties
that permit functioning for health, such as ridding the body of toxic
pollutants which interfere with enzymal functions. Chelation Therapy
operates at a level that is basic for the health of
individual cells -- optimally functioning cells promote optimally
functioning organs, and these, in turn, optimally functioning systems --
and consequent health. Because virtually all diseases have some
component of production of an excess of free-radicals, Chelation Therapy
can be and often is indicated as curative or supportive for many disease
states, especially chronic diseases. Oxygen atoms and other
chemicals within the body are attracted to other compounds and
atoms forming free radicals during combinatorial stages. Free
radicals damage tissues and promote cartilage decomposition and many
other cascading problems for organs, systems and tissues generally. In
addition, cells cannot eliminate their waste products. Cellular
breakdown occurs leading to deterioration and disease. Over time, the
entire arterial system is slowly disturbed, as are organs and tissues,
all of them composed of individual cells with lowered reserves and
capacities.
There are two explanations for the way EDTA Chelation Therapy works.
Probably both theories or explanations are correct. One theory is the
free radical theory; the other is the calcium binding theory, the
removal of calcium that binds together the ingredients of placques in
our arteries.
Free Radical Theory
According to the free radical theory, perhaps 80-90% of all disease
process is an excess of free radical activity11,
12, 13, 14, 15. Excessive free radicals create havoc by
damaging cells and their DNA, changing biochemicals, damaging cell
membranes and sometimes killing cells outright. Every oxygen factor
also has an anti-oxidant factor in our physiological systems. We, in
other words, are normally capable of neutralizing the harmful effects of
atoms and molecules that have a high affinity for other elements and
chemicals, and would otherwise damage tissue and cells in attaching to
cellular components.
Whenever one side or the other of this oxidation/anti-oxidation,
free-radical system becomes unbalanced, damage accrues. This damage
leads to diseases of the circulatory system, malignancies, inflammatory
conditions and immunologic disorders13.
According to Elmer Cranton, M.D., "The free radical concept explains
contradictory epidemiologic and clinical observations and provides a
scientific rationale for treatment and prevention of many of the major
causes of long-term disability and death: atherosclerosis, dementia,
cancer, arthritis, and other age-related diseases22."
EDTA
chelation therapy removes metals that act as catalysts for the
production of excessive free radical reactions, thus halting the disease
process and/ or repairing the damage. Cranton says that "EDTA can
reduce the production of free radicals by a million-fold24."
Calcium Binding Theory
A
proper diet can also act as a chelator. "The proper program of low-fat,
high-complex-carbohydrate diet and aerobic exericse actually is
partially a natural process of chelation therapy.23"
Specific foods and combinations of foods can, then, act as partial
chelators. The extent and distribution of these foods would be too
lengthy for this volume. However, as an example, specific studies have
been completed on the chelating effects of garlic which show that
garlic has a chelating effect on those suffering excessive lipid
deposits. Benjamin Lau, M.D., Ph.D., who has accomplished a great deal
of research on garlic, shows that the ratio of Low Density Lipids to
Very Low Density Lipids decreased in a study over a period of six months
using a particular form of aged garlic , 1 gram per day. At the same
time, with the same ingredients and same dosage, Cholesterol also
decreased. In both instances during an initial 60 day period, the
measurable levels of lipids increased, which was interpreted as an
initial sloughing off of the excessive lipid deposits, after which a
continuous decrease was discovered20.
Gradually, free radicals affect tissues so that localized accumulations
of lipid-containing (oil/fat) material (atheromas) within or beneath
the intima (lining of vessels) surfaces of blood vessels clog up
the 100,000 miles of capillaries, veins and arteries7.
Exposure to pollutants over a lifetime from food, air, water and drugs
collect in various tissues throughout the body, in various ways.
When EDTA chelates out many of these pollutants we find that we can
now handle life better than before and we are healthier.
When EDTA binds with calcium, the consequence is the break-up of the
plaque hindering the flow of blood in the arterial system. Probably, for
many people, plaque formation in the arterial system begins sometime
after birth about ages 4, 5 and 6 and continues onward until more than
50% of the system is plugged, and blood has a difficult time flowing,
and thence disease conditions become evident. Military records show on
autopsies from Korean and Vietnam conflicts that many United States'
soldiers aged 18-25 had coronary artery disease16.
Even two of the three pioneer astronauts who died in the notorious
oxygen fire prior to take-off -- three men picked for their excellent
physical condition -- showed signs of atherosclerosis on autoposy.
There is a margin of safety built into every organ, and the circulatory
system can compensate for increased demands for many years, until its
flexibility and capacity is decreased to a critical limit.
In the calcium binding theory, calcium acts like a cement-binder, in
that it binds fatty substances together, probably over a scar tissue,
and forms the placque linings that cause the arterial system to decrease
in flow volume. By Chelating out the calcium binder, the plaque
dissolves and increases the diameter of the artery while also increasing
the artery's flexibility.
When a fluid flows through a pipe or tube, the rate of flow
depends on a number of factors, including the pipe's length, its
radius, the fluid's viscosity and the time of flow. All other factors
staying constant, a very small decrease or increase in the
radius of the tube decreases or increases the rate of flow,
respectively, by a factor of the power of three. Since a smaller
vascular opening also requires higher blood pressure to pump the blood
through, more work is placed on the heart and overall vascular
system. With increased clogging of the circulatory system, therefore,
our blood pressure increases while the quantity or volume of blood flow
decreases drastically8.
Since the human vascular system is not rigid, like metal pipes, the
subject of cross-sectional diameter and fluid flow can be
over-simplified, as the arteries may also stretch with higher pressure,
therefore compensating to some extent for a smaller diameter of flow
openings. However "perfusion scans have demonstrated increased brain
blood flow after Chelation treatment . . . doppler ultrasound studies
in sample groups of up to 30 patients have demonstrated some cases of
complete patency [the condition of being wide open] of carotid arteries
following treatment . . . [and] there is a 28% improvement or
enlargement of the lumen [inner lining] diameter . . . improvement in
brachial-ankle blood pressure ratios . . .23"
according to Zigurts Strauts, M.D. A 10% increase in vascular diameter
of the arteries is enough to double the blood flow43."
As atherosclerosis progresses, and the pipes — the capillaries,
arteries and veins — decrease in size, each cell of our body also
receives considerably less nourishment than before partial clogging, as
the amount of nourishment lessens with the decrease of blood flow.
There is literally less opportunity to bring molecular food particles
and oxygen to each cell. With less food and oxygen at each cell, the
cell has less capacity to function. Less functioning of each cell
means less ability to resist disease and stress, and less ability to
repair damage already done. That, of course, means increased
opportunity for every kind of disease7!
How Are Treatments Given?
The chemical EDTA, an amino acid, acts like a magnet for positively
charged calcium and other metal ions. The chemical EDTA “claws” onto
the metallic ions and converts them to a chemical that is solvent,
safe and easily washed through urine. While EDTA to some extent also
flushes out beneficial compounds and elements, such as zinc and Vitamin
B6, these beneficial
substances are replaced during the chelating process. A mixture of EDTA
and vitamins and minerals is placed in an intravenous solution, and the
patient takes an intravenous drip for about 3-1/2 hours in a
clinic's out-patient room. The patient usually sits beside others
who watch television or read or simply visit with one another.
According to physicians who routinely use Chelation Therapy with their
patients, it takes about 20 to 22 treatments for first results to
make themselves known to the patient. Depending on severity of the
patient’s overall problems, s/he may need 30, 40,...., 100
treatments given, usually, at the rate of about three per week which,
according to some physicians, is an optimum frequency of treatment.
Other physicians may vary the frequency of treatment, depending upon the
patient's condition. Evaluation of the patient should be made at 3, 6
and 12 month intervals9.
For the treatment to be maximally effective, good dietary habits and
appropriate exercise are important. Alcohol, drugs (including many
prescription drugs) and smoking will reverse the whole process,
again causing free-radical damage that leads to atherosclerosis
and subsequent disease problems that occur as a secondary
condition of the inability of cells to receive their proper
nourishment. Physicians who provide patients with EDTA Chelation Therapy
will also counsel on the negative effects of bad diet and consumption of
alcohol, drugs and smoking. They will advise appropriate diets that will
either assist in the chelating process or will, by themselves, provide
the body with natural chelating mechanisms.
EDTA should not be used during pregnancy9.
Chelation Therapy should normally be postponed until active liver
diseases are properly treated or resolved, unless there is no other
choice available9.
Usually a physician will supplement EDTA treatment with proper diet
counseling and antioxidants which are synergistic with the benefits of
EDTA. These are Vitamins C, E, beta carotene, selenium, glutathione and
a spectrum of B complex vitamins. Iron and copper are free radical
catalysts and excesses may counteract the benefits of chelation therapy9.
EDTA Safety
Any drug can be dangerous under the right conditions, to the wrong
person. Even milk can be exceptionally dangerous to one who is allergic
to it. According to the manner in which drug safety is determined EDTA
is about 3-1/2 times safer or less toxic than taking aspirin6.
This measure is taken from a standard known as the LD-50, the Lethal
Dosage at which 50% of experimental animals will die in a
specified period. "More than 500,000 patients have been treated in the
United States alone, without a single reported incident of renal failure
or death since 196043."
As with any treatment, EDTA can be misused by those who do not
follow a proper treatment protocol, and it is recommended that
physicians use the protocol developed by The American College
for Advancement in Medicine7.
This pioneer organization has long sought to establish certification
and standards of practices including appropriate training and education
for all those physicians who wish to chelate patients.
What Conditions Are Benefited?
Some time after John Parks Trowbridge, Sr. retired from the U.S. Air
Force, at age 70, it was discovered that he had an aortic aneurysm, a
balloon-like swelling in the wall of the main artery. As this condition
indicates a weakened structure that is likely to break and lead to quick
death, he consulted with several physicians, including his son, John
Parks Trowbridge, Jr., M.D. who, along with other physicians,
recommended immediate surgery, which was accomplished. It was not until
several years passed that the younger Trowbridge came to understand the
benefits of Chelation Therapy, learning first from Robert Haskell, M.D.,
who told him, "Of all the regimens you can use to help your patients
combat degenerative disease and restore their health, chelation therapy
is the most powerful. It produces the greatest number of benefits to the
body -- far beyond those of improved blood flow. If you want to get your
prescribed nutrition to those parts of the body in which they must work,
John, chelation therapy is the way to do it39."
The primary reason for recommending Chelation Therapy to you when you
have degenerative disease or have aged has to do with its ability to
restore your vital functions. Virtually everyone has some degree of
clogging up of the 100,000 miles of plumbing. Often the process of
atherosclerosis begins in children’s arteries and progresses through
adulthood, so that even the finest physical specimens show evidence
of this beginning on autopsy. It is virtually certain that you have
some of this clogging, to some degree, and that it
contributes to your state of health at least indirectly.
EDTA intravenous Chelation Therapy has proved to be safe and effective
in the treatment of many varied disease conditions related to abnormal
or diseased vascular conditions. Because this therapy involves the
vascular system, and because blood flow affects every cell in the body,
it is not surprising to find a wide ranging set of lack-of-health
conditions improved or outright cured after its use. According to James
J. Julian, M.D.2,
EDTA Chelation Therapy reduces "toxic metal deposits, abnormal calcium
deposits, blood cholesterol, blood pressure, leg cramps, pigmentation,
varicosities, size of kidney stones. [It] improves circulation, skin
texture and tone, vision, hearing, liver function. [It] relieves to
various degrees: digitalis toxicity, lead toxicity, symptoms of
senility, pain, symptoms of irregular rhythm, hypoglycemia, phlebitis,
scleroderma, skin ulcers, and Wilson's Disease," a disease of the liver
thought to be related to copper.
Doctor's who use disodium EDTA Chelation Therapy would agree with James
Julian. Morton Walker D.P.M. quotes Rudolph Alsleben, M.D. and Wilfrid
E. Shute, M.D.5
who have asserted that beneficial effects are: "prevents the deposit of
cholesterol in the liver, reduces blood cholesterol levels, causes high
blood pressure to drop in 60 percent of the cases, reverses the toxic
effects of digitalis excess, converts to normal 50 percent of cardiac
arrhythmias, reduces or relaxes excessive heart contractions, increases
intracellular potassium, reduces heart irritability, increases the
removal of lead, removes calcium from atherosclerotic plaques, dissolves
kidney stones, reduces serum iron, protects against iron poisoning and
iron storage disease, reduces heart valve calcification, improves heart
function, detoxifies several snake and spider venoms, reduces the dark
pigmentation of varicose veins, heals calcified necrotic ulcers, reduces
the disabling effects of intermittent claudication, improves vision in
diabetic retinopathy, decreases macular degeneration, and dissolves
small cataracts."
William J. Mauer, D.O., according to Walker5,
also provided an additional listing gathered from his own and the
experience of other physicians. These include: "Eliminates heavy metal
toxicity, makes arterial walls more flexible, manages excess quantities
of fat in the blood, prevents osteoarthritis, causes rheumatoid
arthritis symptoms to disappear, has an antiaging effect, smooths skin
wrinkles, offers psychological relief, assures the presence of adequate
zinc in the blood, lowers insulin requirements for diabetics, and
dissolves large and small thrombi."
Other physicians have listed other health improvements, including
reversal of impotence, when impotence is caused by blockage or decreased
flow of blood.
Heart Disease
According to Arabinda Das, M.D.26,
in speaking of heart disease "In the U.S. 600,000 sudden deaths occur
each year. This is one death from coronary heart disease every 32
seconds. Per capita expenditure for treatment of coronary artery disease
is $160 per year for every individual in the U.S. Coronary artery
disease is one of the foremost diseases of this country and the number
one killer. This dangerous condition develops when the blood supply to
the heart muscle is impaired, usually by a narrowing process leading to
stenosis. This may be due to plaque formation or atherosclerosis or
spasming.
"In the U.S. the diagnosis is made with vast amounts of expense,
provided by the insurance companies and still carry serious
complications after treatment. . . . Complications of acute heart
attacks include the heart's failure to pump enough blood (congestive
heart failure), acute pulmonary edema, bronchitis, cardiac asthma,
collapse (shock due to arterial blood circuit with loss of blood
pressure); ineffective heart rhythm, such as the multiple
supraventricular extra systole, leading to ventricular tachycardia,
frequent fatal ventricular fibrillation; travelling blood clots (emboli)
to brain, dilations of heart muscle, and ventricular aneurysm. These are
the ways patients die at home or are brought to hospitals for
intensive care."
The American Heart Association34,
in its 1992 Heart and Stroke Facts report, says 980,000
Americans died of cardiovascular disease in 1988, the latest year for
which figures are available. Women accounted for . . . 51%. ". . . more
Americans died of cardiovascular disease in 1988 than succumbed to
cancer, accidents, pneumonia, influenza, suicide and, AIDS combined."
Chelation vs By-Pass Surgery and Angioplasty
According to the American Heart Association34,
"The disease cost to the nation is staggering . . . an estimated $108.9
billion in health services and lost productivity this year alone."
According to Zigurts Strauts, M.D.23
". . . there are close to 300,000 bypass procedures done in the
United States annually and 5,000-7,000 angioplasties. There is, at the
most conservative estimates, a 1.4% mortality rate in the top centers of
the United States for bypass surgery and a mortality rate approaching 2%
for angioplasty. In California, . . . , the mortality rate on count in
1987 was 4.7%. One out of 20 people therefore do not walk out of the
operating room. We are talking about 15-20 thousand deaths
annually due to these two procedures. The morbidity statistics are no
better. In fact, it is said that up to 20% of patients going through
bypass surgery have at least minimal brain dysfunction and numerous
other cases involving other complications have been reported in the
literature. Kidney failure is one of them. . . . research has been done
measuring ejection fractions [of the heart] of Chelation therapy in
patients and the results have shown a significant improvement. . . .
This cannot be said for bypass surgery where the improvement is only
minimal at best and then only in a few patients. In fact, the patients
with poor ejection fractions are not accepted as bypass candidates. One
could say therefore that for those patients Chelation Therapy may be the
only hope that they have."
Zigurts Strauts' 1987 report does not seem to be affected by the passage
of time. Most recent studies have concentrated on segregating out
classes of patients that have averaged out to his reported 4.7%
California mortality rate.
Severity of initial disease, age of patients, type of heart condition,
surgeon skill, hospital surgery load and so on have all provided grist
for the statisical evaluation mill.
E.L. Hannan36, et.
al. reported that "for all patients receiving coronary artery bypass
surgery in New York State in 1989, . . . demonstrate that both annual
surgeon volume and annual hospital volume are significantly (inversely)
related to mortality rate. Coronary bypass operations performed in
hospitals with annual bypass volumes of 700 or more by surgeons with
annual bypass volumes of 180 or more had a risk-adjusted mortality rate
of 2.67% in comparison to a risk-adjusted mortality rate of 4.29%." In
other words, the more experienced the surgeon, the less the mortality
rate, an obvious conclusion. So, if the mortality rate overall is still
close to 4.7%, there must be something more drastic wrong with the
procedure -- or the vast majority of operations are being performed by
inexperienced surgeons in low-volume hospitals.
O'Connor37 et. al.
reported in 1989 that "the overall crude in-hospital mortality rate for
isolated Cardiac Artery By-pass Grafting was 4.3%." The rate varied
among centers . . . but they concluded "that the observed differences in
in-hospital mortality rates among insitutions and among surgeons in
northern New England are not solely the result of differences in case
mix . . ."
J. Zelen38, et. al.
reported on a variation of mortality rate from 4% for simple, 14.7% for
complex, and 5.3% for all Cardiac Artery By-Pass Grafting operations at
a University medical center in Greater New York.
From a survey of current research literature it is clear that selection
of patients to improve survival outcome can be made on the basis of age,
physician, hospital and type of disease, but it is equally clear that
overall survival rates show very little, if any statistical difference
from those reported in 1987.
By-Pass Surgery and Angioplasty
By-pass surgery involves the replacing of a defective artery, usually
near the heart, with a less defective vein from somewhere else in the
body, usually the leg. The vein is thinner than the artery and not
exactly the artery's equivalent as a replacement. It can be weaker.
There are about 100,000 miles of tubing -- capillaries, veins and
arteries -- in the circulatory system. Although the region near the
heart, with increased turbulence of blood flow, is most likely to be
blocked by plaques, blockage will also be found throughout the arteries.
It is unlikely that replacing one foot of 100,000 miles of blocked
circulation will have more than a temporary palliative affect, except
for a limited and well-defined condition.
By-pass surgery is exceedingly expensive, supporting costly hospital
rooms and staffs, expensive surgical equipment, and high professional
fees.
But the main reason for avoiding by-pass surgery is that it has been
found to be relatively ineffective (with the exception of certain
infrequent conditions). As Morton Walker D.P.M. reports, "Henry D.
McIntosh, M.D., of the Methodist Hospital in Houston, Texas, said at a
symposium of the American Heart Association in Miami Beach that bypass
surgery should be reserved for patients with crippling angina who
did not respond to more conservative treatment.19"
Dr. McIntosh's statement has since been supported by many studies,
including some reported by the Institute of Health, and by some of the
very same physicians who pioneered in heart by-pass.
What sense, then, to have bypass surgery? And especially what sense when
all of the medical literature has already demonstrated its failure
except in a very limited diagnosis of crippling angina?
The diseases that chelation can improve as a matter of routine
include many of the intransigents. Instead of cutting off a gangrenous
leg, the leg is healed, according to Norman E. Clarke and Warren M.
Levin. Instead of expensive heart bypass surgery, the patient is
healed. Instead of Carotid Artery bypass, the brain is again
nourished. Senility and Alzheimers Disease can be reversed provided
brain cells have not been starved of oxygen to the point where they have
died. Other diseases that stem from failing organs due to lack
of nourishment, including the skin, may be halted or reversed7.
Retrospective Study of Chelation Therapy
Philip Hoekstra, Sr. and John M. Baron, D.O.3,
founders of Cypher, Inc. of Ohio, along with other physicians and
Ph.D.s, funded one of the first objective studies, an unpublished
clinical analysis on the use of Chelation Therapy from clinical data
gathered over fifteen years, and involving 20,000 patients.
Statistical evaluations were performed by an independent
organization, free from all bias. Their retrospective study
unequivocally proved that Chelation Therapy solves the problem
in 80% of the cases of clogging in peripheral circulation and
also the Carotid Artery preventing blood from reaching the brain,
intermittent claudication, and reverses Osteoporosis (a 1% sampling),
placing calcium back into bones and teeth, where calcium belongs.
In the Chelation Study, the 20,000 patients came from many
different clinical settings, and they represent patients with a
wide diversity of disease conditions.
The cost of the study was funded privately, and not paid by
any pharmaceutical company. The main ingredient, a chemical titled
in brief as EDTA (Ethylene Diamine Tetracetic Acid), is not
protected by patent. No pharmaceutical company can pay large
returns to stockholders from its sale. No heart surgeon can assess
tens of thousands of dollars applying it to heart problems. No
hospital can submit bills of tens of thousands of dollars more for use
of its operating rooms and services when EDTA is given.There are
recent reports, however, that a large pharmaceutical company is funding
a $6,000,000 double-blind study on a chelating substance (Magnesium
EDTA) for which they hold some or all of the patent rights21.
Elmer Cranton, M.D. states that "Magnesium is a calcium antagonist,
relatively deficient in many chelation patients, and is the metallic ion
least likely to be removed by EDTA. In fact, EDTA is best administered
as magnesium-EDTA, providing an efficient delivery system that increases
magnesium stores.25"
Heart Study
H. Richard Casdorph, M.D., PhD.27 reported
on "18 patients with documented arteriosclerotic heart disease" using a
technetium isotope to measure the left heart ventricular ejection
fraction "before and after the administration of EDTA chelation therapy.
. . A statistically significant improvement in left ventricular ejection
fraction occurred in this group of patients."
Retrospective Study of 2,870 Patients With Atherosclerosis and Other
Degenerative States
Efrain Olszewer, M.D. and James P. Carter, M.D., Dr. P.H.33
presented a 28-month retrospective analysis of 2,870 patients
with documented atherosclerosis and other degenerative, age-associated
diseases who were treated with intravenous disodium magnesium EDTA
chelation therapy. Marked improvement occurred in 76.9% and good
improvement occurred in 17% of treated patients with ischemic heart
disease. Marked improvement occurred in 91% and good improvement
occurred in 8% of treated patients with peripheral vascular disease and
intermittent claudication. In patients with cerebrovascular and other
degenerative cerebral diseases, 24% had marked improvement, and 30% had
good improvement. Of four patients with scleroderma, three had marked
improvement and one had good improvement. Seventy-five percent of all
patients had marked improvement in symptoms of vascular origin.
Independent of pathology, 89% of all treated patients had marked or good
improvement."
The First Published
Double-Blind/Single-Blind
Crossover Study
Efrain Olszewer, M.D., Fuad Calil Sabbag, M.D. and James Carter, M.D.,
Dr.PH conducted the first study to be published involving first a
double-blind and then a single-blind study, using those who were on the
placebo in the single-blind after the code was broken for the
double-blind. "Ten male patients with peripheral vascular disease, . . .
, were randomly assigned to receive either Na2
ethylene diamine tetra acetic acid (EDTA) plus MgSO4,
B complex, and vitamin C, or a placebo of MgSO4,
B complex, and vitamin C. . . . A total of 20 Intravenous Infusions
were planned for administration to each patient. Clinical and laboratory
. . . tests showed dramatic improvements after 10 infusions in some
patients, and thus was broken the code indicating who was receiving EDTA
and who was receiving placebo. The group that improved had been
receiving EDTA; there was no change in the placebo group. The trial was
then completed in a single-blind fashion. Patients originally assigned
to receive placebo then received 10 EDTA Infusions, while the group
originally assigned to EDTA received 20 EDTA Infusions. The group that
had formerly received placebo showed improvements comparable to those
seen in the first EDTA group after 10 treatments43."
Brain Disorders
Casdorph38 also
reports on "fifteen patients with well-documented impairment of cerebral
blood flow," also using technetium isotope. He says, "A highly
significant improvement (p = .0005) in cerebral blood flow occurred
following approximately twenty intravenous infusions of disodium EDTA.
All fifteen patients improved clinically, including one with little or
no improvement in cerebral blood flow."
Cerebral Vascular Arterial Occlusion
E.W. McDonagh, D.O., FACGP, C.J. Rudolph, D.O., Ph.D. and E. Cheraskin,
M.D., D.M.D.29 in a
study of fifty-seven patients evaluated for cerebral vascular arterial
occlusion "Measurements of arterial occlusion were made with the
relatively simple, noninvasive oculocerebrovasculometric analysis.
Cerebrovascular arterial occlusion diminished by an average of 18% (from
a mean of 28% to a mean of 10%) following therapy (P<0.001).
Eighty-eight percent of patients treated with EDTA chelation therapy
showed objective improvements in cerebrovascular blood flow."
Peripheral Vascular Stenosis
McDonagh, Rudolph and Cheraskin30 also
studied "117 lower extremities in 77 elderly patients with documented
occlusive peripheral vascular stenosis, diagnosed by the Doppler
systolic ankle/brachial blood pressure ratio. . . ." revealing "that
intravenous ethylene diamine tetraacetic acid (EDTA) chelation therapy
with supportive multivitamin/trace mineral supplementation improved
arterial blood flow significantly after approximately 60 days and 26
infusions (P<0.001)."
Peripheral Arterial Occlusion, an Alternative to Amputation
H. Richard Casdorph, M.D., Ph.D. and Charles H. Farr, M.D., Ph.D.31 presented
four patients, "each of whom represents end-stage occlusive peripheral
arterial disease with gangrene of the involved extremity. These patients
had exhausted all traditional forms of therapy and they had all been
referred for surgical amputation. Instead of surgery, intravenous EDTA
chelation therapy was instituted with complete success in each case.
These gangrenous extremities all healed and were saved from amputation.
Long-term follow-up, extending for more than a year, indicates that all
four patients are continuing to do well, with their previously
gangrenous extremities intact and pain free. Adjunctive therapies
included vitamin and mineral supplementation and, in two cases,
hyperbaric oxygen therapy (HBO)."
A
Case of Chelation Therapy
Warren Levin, M.D35.
says: "I guess my favorite chelation story is about the psychoanalyst
who was on the staff of a major medical center -- one of the
institutions that I call a mosque in this Mecca of American Medicine
that is New York City. I first saw him as an emergency. He was in his
fifties and looked remarkably healthy, except that he was in a
wheelchair. I asked him what the emergency was and he said that he had
been told he needed an amputation. It turns out he had awakened the same
morning that I saw him to discover that his lower leg was cold, numb,
mottled, blue, with two black-looking toes. He had immediately hied
[hastened] himself over to his hospital and had a consultation with the
chief of vascular surgery. The recommendation was for an immediate trip
to the operating room to amputate above the knee in the hope of saving
the rest of his leg. I don't know where he had heard about chelation
therapy, but he asked this world-renowed surgeon about the possibility
of using chelation in this situation. He was told, 'Don't bother me with
that voodoo,' -- that if he was going to have a good result, it required
surgery. Well, he decided to get a second opinion, so he just crutched
down the hall a couple of doors to one of the associate professors. He,
too, suggested immediate amputation, but when asked about chelation
therapy, the response was, 'Well, this is not yet infected. It looks
like dry gangrene, so you have a little time. You can try it if you
want, but it's a waste of time.' With that as his only hope, [the
psychoanalyst] showed up in my office.
"We started emergency chelation the next day, and after about nine
chelations[one taken] every other day, he was pain-free and pinking up,
and after about seventeen chelations, he was walking on the leg again!
"So, he never had an amputation, and he lived the rest of his life with
not only two legs but all ten toes. It's incredible that I never got a
phone call from either of these two surgeons who are just blocks away
from my office to say, 'Hey, what the hell did you do Levin?' and I am
certain that the next patient with a similar problem that showed up in
their offices was told that the only thing to do is to amputate. What a
tragedy."
Preventive Reduction in Cancer Mortality
Walter Blumer, M.D. and Elmer M. Cranton, M.D.32 report
that mortality from cancer was reduced 90% during an 18-year follow-up
of 59 patients treated with calcium-EDTA. Only one of 59 treated
patients (1.7%) died of cancer while 30 of 172 nontreated control
subjects (17.6%) died of cancer (P = 0.002). Death from atherosclerosis
was also reduced. Treated patients had no evidence of cancer at the time
of entry into this study. Observations relate only to long term
prevention of death from malignant disease, if chelation therapy is
begun before clinical evidence of cancer occurs."
Claudication and Joint Deformation
Before trying Chelation Therapy , one 58 year old male4
patient prepared a detailed list of symptoms, or at
least perceived symptoms, of what the felt was wrong and would like to
have corrected. Since the patient didn’t know what the treatment would
do, he simply wrote down everything he didn’t like about himself or
felt was physically or emotionally wrong. He also planned to have
a number of periodic laboratory tests during the course of his
chelation treatments. He wanted to be able to evaluate for himself
what was true or not true about this new form of treatment.
There were many items listed that did not change under Chelation
Therapy. But those symptoms that did change were quite striking and
are among clinical signs and symptoms that no amount of traditional
drug treatment would have solved. He had to lie down at three o’
clock every afternoon to rest for three to six hours. He often felt
like the world could come to an end, and he’d not care. Also
whenever he lay down his legs cramped terribly. This kind of pain
and muscle cramping is known as “claudication,” and can be a product
of calcium insufficiency and/or oxygen lack, both of which can stem
from lack of proper cellular nourishment.
Pain and inflammation in one joint on one little finger would not
respond to various treatments and medicines tried by his family
doctor. Probably the reason — deduced after the fact — is that iron
from vascular blood leakage acted as a catalyst that cycled through
a chemical reaction resulting in the decomposition of the
cartilage. And, as the cartilage decomposed into various forms of free
radicals, those, in turn, created additional secondary and tertiary
effects, thence leaving the iron radical free to begin the cycle again.
It could not have been halted without chelating out the free iron
catalyst.
After three treatments by Chelation Therapy, the little finger joint
inflammation disappeared entirely for the first time in two years.
Claudication disappeared at about 22 treatments given over eight
weeks. It didn’t disappear suddenly, but gradually, over several
treatments, the cramping and pain lessenening each time. Extreme
tiredness disappeared after 30 to 40 treatments, ten to fourteen weeks.
In all this patient had 81 chelations over the next 6 years.
No
other known traditional treatment, no amount of taking of known drugs
to control symptoms could have brought about the improvements noted.
The patient is now 67 years of age (1992) and dances with ladies a
generation younger than he is from three to four times each week. His
dancing is not nice, sedate, "safe" ballroom dancing, but rather the
modern version of the wildly active jitterbug of the forties, only now
called "Bop" (East Coast and West Coast Swing). It is fascinating to
watch younger ladies cave in under this strenous exercise, while the
old-timer -- who was hardly fit at one time -- continues from lady to
lady without any sign of exceptional breathing!
Glaucoma
Glaucoma is traditionally treated by means of medicines that control the
inflow or defects in drainage of intra-ocular fluid. In the
traditional approach only symptoms are being treated, not the causation
of imbalance in intra-ocular fluids. Since "simple glaucoma is the
effect in the eye of a disturbance of the water-salt economy of the
body, there must be a drop in the chemistry of the blood, such as a drop
in sodium salts, a rise in potassium salts, and a rise in blood
cholesterol.17"
According to John Baron, D.O. of Ohio most Glaucoma is not a problem
simply of the eye, but rather a problem that is systemic; i.e., pervades
the whole body -- the eye being simply one physical manifestation of the
total problem.
A
thermograph of the neck and head will tell whether or not the patient is
getting sufficient blood to his facial features. If he is not, the
patient is a candidate for Chelation Therapy, as he most probably
suffers from progressive atherosclerosis. The glaucoma can be a result
of vascular disorder arteriosclerosis of the optic artery', which means
insufficient blood to the eyeball, etc. Only Chelation Therapy has a
chance of solving that problem if it has not gone too far. Again you
need a doctor who specializes in this kind of treatment and uses the
correct protocol. In addition to Chelation Therapy, one needs to look
after one's general health, which means decreasing stress and improving
dietary and nutritional intake. If it is not a problem of blood flow,
then you have a different situation, and the use of adrenal cortex
hormone will be useful in any case, until you have the intra-ocular
pressure under systemic control.
Toenail Fungus Infection
John Parks Trowbridge, Sr. suffered from fungus infection of the
toenails after trips to the Orient while serving the United States Air
Force. Twenty five years of medical attention could not rid him of this
scourge. Administration of Chelation Therapy alone did so, and he said,
"After my chelation therapy, the big toes have grown healthy nails that
came in behind and shoved the diseased nails off39."
Generalized Benefits
According to Morton Walker41,
D.P.M., John Sorenson is ecstatic with the changes in himself. Sorenson
says, ". . . major benefits [include]: improved hair growth, freedom
from headaches, a good memory, ability to think clearly, no aches and
pains except from physical injuries, clear vision, the ability to walk
up to eight miles a day, weight loss to a normal 175 pounds, reversal of
impotency, a healthy, tough, and flexible skin, a better skin color,
bright red blood color versus muddy looking blood, no skin eruptions,
wounds that heal twice as quickly as before, and no hyperacidity. I have
won back 25 years of my life. At age 68, I am doing more and better work
than I did at age 40 . . .
"Since taking chelation therapy my life has been a constant process of
improving health, happiness, and productivity."
Eliminating Pollutants and Damaging Metallic Ions
Anything you can do to better nourish (and oxygenate) individual
cells, you should do, to relieve the burdens that you already carry.
Anything you can do to avoid pollutants in water, food, and air you
should do. One example, of a recently hidden negative, is the use of
chlorine in drinking water as a disinfectant. The "Environmental
Protection Agency study showed that drinking highly chlorinated water
'subtly but noticeably shifted' a mouse's transport of cholesterol from
high-density lipoproteins (the 'good' lipoproteins) in the blood to the
'bad' low-density lipoproteins, which foster atherosclerosis." J. Peter
Bercz, who headed the study, reported that hypochlorite, a very reactive
by-product of standard water chlorination, "can also destroy
polyunsaturated fatty acids . . . , including those essential to health42."
Multiply this single effect of a standard, assumed-to-be-safe
disinfectant of water, by the thousands of impurities found in air and
food. Pure food, water and air are extremely important! But more — EDTA
will also help you to eliminate many of these pollutants that are
acquired over a lifetime, the same that contribute in so many ways to
your overall condition. In addition, by stimulating a gland called the
parathyroid, your body will reverse the flow of calcium to harden bones
and teeth, thereby reversing Osteoporosis.
Investigative Medical Journalist
Morton Walker D.P.M. says, "Usually, the conclusion that an objective
observer draws, especially someone trained in science and medicine, like
myself, is that . . . More often than not anecdotal medicine is nothing
more than 'buffaloe dew.'. . . In the past I have believed that to be
true. But what must an investigative medical journalist do when . . .
exposed to story after story and to one case history after another that
reports potentially imminent death, blindness, amputation, paralysis and
other problems among people, and upon visiting those people to check
their stories, he sees them presently free of all signs of their former
health problems. This has happened to me! About 200 individuals who were
victims of hardening of the arteries are much changed. . . . they are
vibrant, productive, youthful looking, vigorous, full of zest for life,
and they enthusaistically endorse chelation therapy as the cause of
their prolonged good health.
"I have . . . turned up not a single untruth40."
Where To Get Help
There are a large number of physicians throughout the world who now
routinely offer Chelation Therapy to their patients. The best source for
finding a physician in your area is the American College of Advancement
in Medicine (ACAM), 23121 Verdugo Dr., Suite 204, Laguna Hills, CA
92653. Its members of physicians and scientists meet semi-annually
where professional papers and discoveries are presented by other
physicians and scientists. One can get acquainted with the latest
research discoveries by other physicians and scientists and the latest
treatment protocol recommendations. This organization will also refer
you to good sources of valid materials as well as provide sources of
rebut against those who unwittingly seek to halt this great, new
therapy.The Rheumatoid Disease Foundation, a non-profit, charitable
organization, also has a listing of physicians who will perform
Chelation Therapy. Send a legal size, stamped, self-addressed envelope,
along with a tax-exempt donation to handle cost of handling when
requesting information from The Rheumatoid Disease Foundation at 7111
Sweetgum Drive SW, Suite A, Fairview, TN 37062-9384. Additional sources
may include many physicians who are oriented toward the practice of
Preventive or Holistic Medicine, but always assure that the physician
you choose is a member of and accredited by the American College of
Advancement of Medicine.
Additional valuable resources are any or all of the books and
references below.
References
1. American College of Advancement in Medicine (ACAM), 23121 Verdugo
Dr., Suite 204, Laguna Hills, CA 92653.
2. James J. Julian, M.D. ,Chelation Extends Life, Wellness
Press, 1654 Cahuenga Boulevard, Hollywood, CA 90028, p. 31, 1982.
3. Baron, John M. D.O. personal interview and unpublished documents.
4. Personal knowledge.
5. Morton Walker, D.P.M., (Gary Gordon, M.D., Consultant)
The Chelation Answer, M.Evans and Company, Inc., p. 18, 1982.
6. Ibid, p. 97, 1982.
7. di Fabio, Anthony, The Art of Getting Well, , The Rheumatoid
Disease Foundation, 7111 Sweetgum Drive SW, Suite A, Fairview, TN
37062-9384, p. 83, 1988.
8. Handbook of Chemistry and Physics, 26th Edition, p. 1637,
viscosity formula 1942;
9. Protocol for the Safe and Effective Administration of Intravenous
EDTA Chelation Therapy, obtained from one of the semi-annual
meetings of the Amercan College of Advancement in Medicine (ACAM) 23121
Verdugo Dr., Suite 204, Laguna Hills, CA 92653.
10. Halstead, Bruce,The Scientific Basis of EDTA Chelation Therapy,
Golden Quill Publishers, Inc., 1979.
11. Farr, Charles H., M.D., PhD, White, Robert L. P.A.C., PhS.,
Schachter, Michael, M.D.,Chronological History of EDTA Chelation
Therapy, Revised October 1991.
12. Butterfield, J.B, "Free Radical Pathology and it's
Involvement in Chronic Disease Processes", Stroke 9: 443-445.
13. Cranton, E.M., Frackleton, J.P., "Free Radical Pathology in
Age-Associated Diseases", Journal of Holistic Medicine 6:1.
14. Collin, Jonathan, M.D., "Free Radical Pathology and Chelation
Therapy", Townsend Letter for Doctors. 1984.
15. Carter, James P., Olszewer, Efrain, "EDTA Chelation Therapy in
Chronic Degenerative Disease", Medical Hypotheses (1988) 27:
41-49.
16. Evers, Ray, M.D., "Chemo-Endarterectory Therapy and Preventive
Medicine", Townsend Letter for Doctors, Feb/Mr. 1986. Issue #49.
17. Josephson, Emanuel M., M.D., "Glaucoma and Its Medical Treatment
With Cortin," JAQA, Vol. 3, No. 1, p. 2-6, Oct. 1987.
18. Morton Walker, D.P.M., (Gary Gordon, M.D., Consultant)The
Chelation Answer, M.Evans and Company, Inc., p.113, 1982.
19. Morton Walker, D.P.M., (Gary Gordon, M.D., Consultant)The
Chelation Answer, M.Evans and Company, Inc., p.175, 1982. Quoting
from Jane E. Brody, "Doctors query bypass surgery as aid to heart."
New York Times, November 22, 1976.
20. Lau, Benjamin, M.D., Ph.D., Garlic Research Update, Odyseey
Publishing, Inc. 2135 West 45th Avenue, Vancouver, B.C., Canada V6M 2J2,
p.2-3, 1991.
21. Personal Conversation with George Klabin.
22. Elmer Cranton, Ed., A Textbook on EDTA Chelation Therapy, Special
Issue of Journal of Advancement in Medicine, Volume 2, Numbers 1/2,
Human Sciences Press, Inc, 233 Spring Street, New York, New York
10013-1578, p. 18, Spring/Summer 1989.
23. Zigurts Strauts, M.D., Townsend Letter for Doctors, p.
382-383, May 1992.
24. Elmer Cranton, Ed., A Textbook on EDTA Chelation Therapy, Special
Issue of Journal of Advancement in Medicine, Volume 2, Numbers 1/2,
Human Sciences Press, Inc, 233 Spring Street, New York, New York
10013-1578, p. 34, Spring/Summer 1989 .
25. Ibid, p. 36, Spring/Summer 1989 .
26. Arabinda Das, "Complementary medical Treatment for Coronary Heart
Disease," Townsend Letter for Doctors, p. 419, May 1992.
27. H. Richard Casdorph, M.E., Ph.D. "EDTA Chelation Therapy: Efficacy
in Arteriorslerotic Heart Disease," Elmer Cranton, Ed., A Textbook on
EDTA Chelation Therapy, Special Issue of Journal of Advancement in
Medicine, Volume 2, Numbers 1/2, Human Sciences Press, Inc, 233
Spring Street, New York, New York 10013-1578, p. 121, Spring/Summer
1989.
28. Ibid, p. 131, Spring/Summer 1989.
29. E.W. McDonagh, D.O., FACGP, C.J. Rudolph, D.O., Ph.D., and E.
Cheraskin, M.D., D.M.D. "An Oculocerebrovasculometric Analysis of the
Improvement in Arterial Stenosis Following EDTA Chelation Therapy,"
Elmer Cranton, Ed., A Textbook on EDTA Chelation Therapy, Special
Issue of Journal of Advancement in Medicine, Volume 2, Numbers 1/2,
Human Sciences Press, Inc, 233 Spring Street, New York, New York
10013-1578, p. 155, Spring/Summer 1989.
30. Ibid, p. 159, Spring/Summer 1989.
31. H. Richard Casdorph, M.D., Ph.D. and Charles H. Farr, M.D., Ph.D. "EDTA
Chelation Therapy: Treatment of Peripheral Arterial Occlusion, an
Alternative to Amputation," Elmer Cranton, Ed., A Textbook on EDTA
Chelation Therapy, Special Issue of Journal of Advancement in Medicine,
Volume 2, Numbers 1/2, Human Sciences Press, Inc, 233 Spring Street,
New York, New York 10013-1578, p. 167, Spring/Summer 1989.
32. Walter Blumer, M.D., and H. Richard Casdorph, M.D., Ph.D. "Ninety
Percent Reduction in Cancer Mortality After Chelation therapy With EDTA,"
Elmer Cranton, Ed., A Textbook on EDTA Chelation Therapy, Special
Issue of Journal of Advancement in Medicine, Volume 2, Numbers 1/2,
Human Sciences Press, Inc, 233 Spring Street, New York, New York
10013-1578, p. 183, Spring/Summer 1989.
33. Efrain Olszewer, M.D. and James P. Carter, M.D., Dr. PH, "EDTA
Chelation Therapy: A Retrospective Study of 2,870 Patients," Elmer
Cranton, Ed., A Textbook on EDTA Chelation Therapy, Special Issue of
Journal of Advancement in Medicine, Volume 2, Numbers 1/2, Human
Sciences Press, Inc, 233 Spring Street, New York, New York 10013-1578,
p. 197, Spring/Summer 1989.
34. American Heart Association, Heart and Stroke Facts, 1992.
35. Personal Communication from Warren Levin, M.D.
36. E.L. Hannan, H. Kilburn, Jr., H. Bernard, J.F. O'Donnell, G. Lukacik,
E.P. Shields, "Coronary Artery Bypass surgery: The Relationship Between
Inhospital Mortality Rate and Surgical Volume After Controlling for
Clinical Risk Factors, Med-Care, Nov 1991, 29(11): 1094-107.
37. G.T. O'Connor, S.K. Plume, E.M. Olmstead, L.H. Coffin, J.R. Morton,
C.T. Maloney, E.R. Nowicki, J.F. Tryzelaar, F. Hernandez, L. Adrian, et.
al. "A Regional Prospective Study of In-Hospital Mortality
Associated with Coronary Artery Bypass Grafting, "JAMA, Aug 14,
1991, 266(6): 803-9.
38. J. Zelen, T.V. Bilfinger, C.E. Anagnostopoulos, Coronary Artery
Bypass Grafting. The relationship of Surgical Volume, Hospital Location,
and Outcome, NY State J Med, Jul 1991 91(7): 290-2.
39. John Parks Trowbridge, M.D., Morton Walker, D.P.M., The Healing
Powers of Chelation Therapy, New Way of Life, Inc., 484 High Ridge
Road, Stamford, CT 06905, 1991.
40. Chelation Therapy, Morton Walker, D.P.M. Freelance
Communications, 484 High Ridge Road, Stamford,Ct 06905, 1980.
41. The Chelation Way, Morton Walker, D.P.M. Avery Publishing
Group, Inc., Garden City Park, New York,1990.
42. "Radical Concerns Over Drinking Water," Science News, Vol.
141, No. 24, June 13, 1992, p. 398.
43. Efrain Olszewer, M.D., Fuad Calil Sabbag, M.D., and James P. Carter,
M.D., Dr. PH., "A Pilot Double-Blind Study of Sodium-Magnesium EDTA in
Peripheral Vascular Disease," Journal of the National Medical
Association, Vol. 82, No.3, March 1990.
44. James P. Frackelton, M.D., "Letters to the Editors," Towsend
Letter for Doctors, July 1992.
45. James P. Frackelton, M.D., "Letters to the Editors," Towsend
Letters for Doctors, p. 604, July 1992.
46. Gordon E. Potter, M.D. "The Blood/Brain Connection,' Towsend
Letter for Doctors, July 1992.
47. Personal Communication from Warren Levin, M.D. to Perry A.
Chapdelaine, Sr.
Recommended Reading
1. Elmer Cranton, Ed., A Textbook on EDTA Chelation Therapy, Special
Issue of Journal of Advancement in Medicine, Volume 2, Numbers 1/2,
Human Sciences Press, Inc, 233 Spring Street, New York, New York
10013-1578, Spring/Summer, 1989.
2. di Fabio, Anthony,The Art of Getting Well, The Rheumatoid
Disease Foundation, 7111 Sweetgum Drive SW, Suite A, Fairview, TN
37062-9384, 1988.
3. Morton Walker, D.P.M., (Gary Gordon, M.D., Consultant)The
Chelation Answer, M.Evans and Company, Inc., 1982.
4. Halstead, Bruce,The Scientific Basis of EDTA Chelation Therapy,
Golden Quill Publishers, Inc., 1979.
5. James J. Julian, M.D. ,Chelation Extends Life, Wellness
Press, 1654 Cahuenga Boulevard, Hollywood, CA 90028, 1982.
6. Protocol for the Safe and Effective Administration of Intravenous
EDTA Chelation Therapy, obtained from one of the semi-annual
meetings of the American College of Advancement in Medicine (ACAM) 23121
Verdugo Dr., Suite 204, Laguna Hills, CA 92653.
7. John Parks Trowbridge, M.D., Morton Walker, D.P.M., The Healing
Powers of Chelation Therapy, New Way of Life, Inc., 484 High Ridge
Road, Stamford, CT 06905.
8. Townsend Letter for Doctors,
911 Tyler Street,
Port Townsend, WA 98368-6541.
9. Roy Kupsinel, M.D, Ed., Health Consciousness, ., PO Box 550,
Oviedo, FL 32765.
10. Morton Walker, D.P.M., Chelation Therapy, Freelance
Communications, 484 High Ridge Road,
Stamford,Ct
06905, 1980.
11. Morton Walker, D.P.M., The Chelation Way, Avery Publishing
Group, Inc., Garden City Park, New York,1990.
Medical data is for
informational purposes only. You should always consult your family
physician, or one of our referral physicians prior to treatment
|
